RT Journal Article
SR Electronic
T1 The plasmablast response to SARS-CoV-2 mRNA vaccination is dominated by non-neutralizing antibodies that target both the NTD and the RBD
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.07.21253098
DO 10.1101/2021.03.07.21253098
A1 Amanat, Fatima
A1 Thapa, Mahima
A1 Lei, Tinting
A1 Ahmed, Shaza M. Sayed
A1 Adelsberg, Daniel C.
A1 Carreno, Juan Manuel
A1 Strohmeier, Shirin
A1 Schmitz, Aaron J.
A1 Zafar, Sarah
A1 Zhou, Julian Q
A1 Rijnink, Willemijn
A1 Alshammary, Hala
A1 Borcherding, Nicholas
A1 Reiche, Ana Gonzalez
A1 Srivastava, Komal
A1 Sordillo, Emilia Mia
A1 Bakel, Harm van
A1 The Personalized Virology Initiative
A1 Turner, Jackson S.
A1 Bajic, Goran
A1 Simon, Viviana
A1 Ellebedy, Ali H.
A1 Krammer, Florian
YR 2021
UL http://medrxiv.org/content/early/2021/03/09/2021.03.07.21253098.abstract
AB In this study we profiled vaccine-induced polyclonal antibodies as well as plasmablast derived mAbs from subjects who received SARS-CoV-2 spike mRNA vaccine. Polyclonal antibody responses in vaccinees were robust and comparable to or exceeded those seen after natural infection. However, that the ratio of binding to neutralizing antibodies after vaccination was greater than that after natural infection and, at the monoclonal level, we found that the majority of vaccine-induced antibodies did not have neutralizing activity. We also found a co-dominance of mAbs targeting the NTD and RBD of SARS-CoV-2 spike and an original antigenic-sin like backboost to seasonal human coronaviruses OC43 and HKU1 spike proteins. Neutralizing activity of NTD mAbs but not RBD mAbs against a clinical viral isolate carrying E484K as well as extensive changes in the NTD was abolished, suggesting that a proportion of vaccine induced RBD binding antibodies may provide substantial protection against viral variants carrying E484K.Competing Interest StatementThe Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines which list Florian Krammer as co-inventor. Viviana Simon is also listed on the serological assay patent application as co-inventors. Mount Sinai has spun out a company, Kantaro, to market serological tests for SARS-CoV-2. Florian Krammer has consulted for Merck and Pfizer (before 2020), and is currently consulting for Pfizer, Seqirus and Avimex. The Krammer laboratory is also collaborating with Pfizer on animal models of SARS-CoV-2. Ali Ellebedy has consulted for InBios and Fimbrion Therapeutics (before 2021) and is currently a consultant for Mubadala Investment Company. The Ellebedy laboratory received funding under sponsored research agreements that are unrelated to the data presented in the current study from Emergent BioSolutions and from AbbVie.Funding StatementThis work was partially funded by the NIAID Collaborative Influenza Vaccine Innovation Centers (CIVIC) contract 75N93019C00051, NIAID Center of Excellence for Influenza Research and Surveillance (CEIRS, contract # HHSN272201400008C and HHSN272201400006C), NIAID grants U01AI141990 and U01AI150747, by the generous support of the JPB Foundation and the Open Philanthropy Project (research grant 2020-215611 (5384); and by anonymous donors. J.S.T. was supported by NIAID 5T32CA009547.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Mount Sinai Hospital Institutional Review BoardAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available upon reasonable request from the corresponding authors.